Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DCA13V
|
|||
| Drug Name |
Leriglitazone
|
|||
| Synonyms |
Hydroxypioglitazone; 146062-44-4; Leriglitazone; Hydroxy Pioglitazone (M-IV); MIN-102; Leriglitazone [USAN]; K824X25AYA; CHEBI:82937; UNII-K824X25AYA; 2,4-Thiazolidinedione, 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-; 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; WHO 10868; Hydroxy Pioglitazone-D5 (Major) (M-IV); 2,4-Thiazolidinedione, 5-((4-(2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy)phenyl)methyl)-; 5-(4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; 1-Hydroxypioglitazone; Pioglitazone, hydroxy; LERIGLITAZONE [INN]; Leriglitazone (USAN/INN); CHEMBL1267; SCHEMBL4098326; DTXSID30399914; OXVFDZYQLGRLCD-UHFFFAOYSA-N; BDBM50530214; ZINC01482947; AKOS015856344; DB15021; 5-[[4-[2-[5-(1-Hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione; HY-117727; CS-0067030; FT-0643388; D11603; A1-01710; J-008187; Q27156475; 5-(4-{2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione; 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione; ALL-AMBO-5-((4-(2-(5-(1-HYDROXYETHYL)PYRIDIN-2-YL)ETHOXY)PHENYL)METHYL)-1,3-THIAZOLE-2,4(3H,5H)-DIONE
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Cerebral X-linked adrenoleukodystrophy [ICD-11: 5C57.1] | Phase 3 | [1] | |
| Company |
Minoryx Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H20N2O4S
|
|||
| Canonical SMILES |
CC(C1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3)O
|
|||
| InChI |
InChI=1S/C19H20N2O4S/c1-12(22)14-4-5-15(20-11-14)8-9-25-16-6-2-13(3-7-16)10-17-18(23)21-19(24)26-17/h2-7,11-12,17,22H,8-10H2,1H3,(H,21,23,24)
|
|||
| InChIKey |
OXVFDZYQLGRLCD-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05819866) A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Minoryx Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.